source
- Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, moreThe FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outl…BioSpace · 12h ago↗ source
- Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warnA Trump administration plan to limit visas for graduate student and postdocs to four years is fueling concerns that the U.S. could lose out on foreign scientists